Journal
IMMUNOTHERAPY
Volume 12, Issue 14, Pages 1067-1075Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0112
Keywords
cost-effectiveness; first-line treatment; immunotherapy; ipilimumab; Markov; nivolumab; non-small-cell lung cancer; PD-L1 positive
Categories
Funding
- National Natural Science Foundation of China [71704064]
- Natural Science Foundation of Guangdong Province, China [2017A030310174]
Ask authors/readers for more resources
Aim:To evaluate the cost-effectiveness of nivolumab plus ipilimumab (NI) in the first-line treatment of patients with advanced non-small-cell lung cancer from a US-payer perspective.Materials & methods:We developed a Markov model to evaluate the cost and effectiveness of NI versus chemotherapy as first-line treatment of NSCLC. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were estimated.Results:NI provided an additional 0.715 QALYs compared with chemotherapy in all population. The corresponding ICER of NI was $180,307 per QALY gained. However, the ICER decreased to $143,434 per QALY in the programmed death ligand 1 expression level Conclusion:From a US-payer perspective, NI is estimated to be cost-effective in the first-line setting for advanced NSCLC patients with programmed death ligand 1 expression level <1%.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available